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Irondeﬁciencyanemiaisthoughttoaﬀectthehealthofmorethanonebillionpeopleworldwide,withthegreatestburdenofdisease
experienced in lesser developed countries, particularly womenof reproductive age and children. This greater disease burden is due
to both nutritional and infectious etiologies. Individuals in lesser developed countries have diets that are much lower in iron,
less access to multivitamins for young children and pregnant women, and increased rates of fertility which increase demands
for iron through the life course. Infectious diseases, particularly parasitic diseases, also lead to both extracorporeal iron loss and
anemia of inﬂammation, which decreases bioavailability of iron to host tissues. This paper will address the unique etiologies and
consequences of both iron deﬁciency anemia and the alterations in iron absorption and distribution seen in the context of anemia
of inﬂammation.Implications for diagnosis and treatment in this unique context will also be discussed.
1.Introduction
Anemia is a worldwide public health problem, with global
prevalence estimated at 24.8% (95% CI: 22.9–26.7). The
majorityoftheglobaldiseaseburdenofanemiaisshouldered
by the developing world, with prevalence in Africa and
S o u t hE a s tA s i aa sh i g ha st w ot h i r d sa m o n gc h i l d r e nu n d e r
ﬁve, and nearly half among women [1]. The World Health
Organization (WHO)has classiﬁed anemia as a severe public
health problem (prevalence ≥ 40%) for children under ﬁve
in 69 countries, and for pregnant women in 68 countries
[1]. The causes of anemia in the developing world are multi-
factorial and include nutritional deﬁciencies, extra-corporal
blood loss, higher prevalence of hemoglobinopathies, and
inﬂammation. These etiologies often coexist and are diﬃcult
to distinguish due to limited diagnostic capabilities in
resource-poor settings. High fertility rates also contribute to
the burden of anemia among pregnant women and infants,
with short interbirth intervals placing women at higher risk
for iron deﬁciency anemia with concomitant increased risk
of iron deﬁciency for the newborn [2–4]. This papaer will
focus primarily on the etiology of iron deﬁciency anemia in
thecontextofinfectiousdiseases endemicinlesserdeveloped
countries.
The WHO notes that anemia is often used as an inap-
propriate proxy for iron deﬁciency, given the coexistence of
many etiologies [5]. Recent studies demonstrate that the role
of anemia of inﬂammation in the pathogenesis of anemia
in the developing world is underestimated [6], as it plays a
central role in the context of infectious diseases prevalent in
these regions [7–14]. Though both iron deﬁciency anemia
and anemia of inﬂammation ultimately lead to host tissue
iron insuﬃciency, it is likely that health outcomes related
to each diﬀer. Improved diagnostic tools to deﬁne etiology,
including multiple concurrent etiologies, are an important
ﬁrst step to understanding how diﬀerent causes of anemia
adversely impact health outcomes. Due to recent advances
in our understanding of the etiology of anemia of inﬂam-
mation, and speciﬁcally the role of hepcidin in altering iron
metabolism, improvementsin diagnostic toolsto distinguish
iron deﬁciency anemia and anemia of inﬂammation will be
increasingly possible.2 Anemia
2.IronDeﬁciencyinthe DevelopingWorld
Iron deﬁciency is thought to aﬀect the health of more than
one billion people worldwide [15]. The WHO/World Bank
has ranked iron deﬁciency anemia as the third leading cause
of Disability Adjusted Life Years (DALY’s) lost for females
of childbearing age [16], and among the top 10 disease
burdensformeninthisagegroup(15–44years)[16].Among
infants, iron deﬁciency is the most common micronutrient
deﬁciency and cause of anemia worldwide [17, 18]. Young
children and women in lesser-developed countries (LDCs)
are most signiﬁcantly aﬀected by iron deﬁciency anemia
[15], which has numerous causes speciﬁc to the developing
world including blood loss due to poor dietary iron intake,
high fertility rates, and fecal iron loss in the context of
parasitic infections such as hookworm, schistosomiasis, and
trichuriasis.
Iron deﬁciency occurs at a higher prevalence among
women than among their male counterparts due to men-
strualironlossesandtheextremeirondemandsofpregnancy
(approximately two times those of a nonpregnant state). The
growing fetus requires a large supply of iron, which is taken
up from maternal blood via transferrin-receptor mediated
endocytosis[19]. Once maternal iron stores are depleted,she
becomes anemic and transfer of iron to the developing fetus
may be compromised [2, 20]. In utero acquisition of iron
determines newborn iron stores [21] and remains associated
with iron status at 9 [22] and 24 months of age [23]. Thus,
infants who are born with insuﬃcient iron stores are unlikely
to reacquire adequate iron supplies, particularly in LDCs
where maternal breast milk may containinadequateiron and
weaning foods are notoriously iron poor. This risk persists,
and even increases, for young children in LDCs where diets
are often poor in bio-available iron, particularly in areas
where iron fortiﬁcation programs are not in eﬀect. Young
children remain a particularly vulnerable group due to the
increased iron requirements during periods of rapid growth,
which are almost 10 times higher per kilogram of body
weight than that of an adult male.
One of the major consequences of iron deﬁciency for
infant health is cognitive impairment, as infancy is a key
period for brain growth and development, and iron uptake
into the brain is maximal during this period [24]. Iron
is required for several important brain functions including
myelination of nerve ﬁbers, energy metabolism, and acting
as a cofactor for a number of enzymes involved in neuro-
transmitter synthesis [21, 25]. Many well-designed studies
conducted in LDCs among infants and young children have
demonstrated that iron supplementation leads to improve-
ments in speciﬁc domains of cognition [26, 27]. Domains
t h a ta r em o r ea m e n a b l et oi r o nt h e r a p yi n c l u d el a n g u a g e
and motor development [26]. Of note, some studies have
found that the eﬀect of treatment is modiﬁed by baseline
characteristics, such that children with poorer nutritional
or hemoglobin status at baseline are more likely to beneﬁt
[28]. Further, many studies have demonstrated impairment
of development even at mild or moderate degrees of iron
deﬁciency anemia [26, 27, 29, 30]. It should be noted,
however, that a number of randomized controlled trials
have demonstrated no beneﬁt of iron therapy on cognitive
performance. This may be due to short periods of followup,
capture of domains of cognition that may not be as sensitive
toiron insuﬃciency,orexamination ofdomainsofcognition
that may be related to iron insuﬃciency, but are no longer
“plastic” or amenable to treatment [31].
Iron deﬁciency is also thought to cause decreased work
capacity [32]. This has more signiﬁcant implications for
LDCs,where a greaterproportionofa nation’s grossnational
product is related to manual labor. In a study based in
China, migrant schoolchildren with severe iron deﬁciency
were found to have decreased aerobic capacity and habitual
physical activity [33]. In addition, studies have been con-
ducted examining the relationship between treatment for
helminth infections and physical work capacity. Studies have
demonstrated increased work capacity following treatment
for both schistosomiasis and hookworm [34, 35]. Though
much of this beneﬁt is likely due to improvements in iron
statuswithtreatment, itshould benoted thatimprovedwork
capacity in these contexts might also be due to improved
nutritional status and reduction in parasite-related symp-
tomatology.
3.InfectiousDiseases andIron Deﬁciency
3.1. Hookworm. Hookworm infection is one of the most
important parasitic diseases in humans in terms of Dis-
ability Adjusted Life Years (DALYs) lost, outranking schis-
tosomiasis, African trypanosomiasis, Chagas disease, and
leprosy [36, 37]. Much of the burden of hookworm is
due to extra-corporeal iron loss [38], and interventions
to treat hookworm infection have demonstrated signiﬁcant
improvements in hemoglobin [39]. Iron-deﬁciency anemia
resulting from chronic intestinal blood loss due to hook-
worm infection often causes long-term morbidity [40, 41].
Blood loss is caused predominantly by parasite release of
coagulases, causing ongoing blood loss in the stool, rather
than actual blood consumption by the parasite. Forexample,
A. duodenale is estimated to cause up to 0.25mL of blood
loss per worm per day [41]. A hookworm burden of 40–
160 worms (depending on the iron status of the host)
is associated with iron deﬁciency anemia [42]. Women of
childbearing age, pregnant women, and young children are
at greatest risk for hookworm-associated iron deﬁciency
anemiaduetolowironstoresresultingfromdietsinsuﬃcient
to meet demands.
The development of hookworm-related iron deﬁciency
anemia depends on the level of an individual’s iron stores,
the intensity of infection, and the infecting species as A.
duodenale causes a greater blood loss than N. americanus.
A study conducted in Tanzania examined 525 school-age
children,comparingthedegreeofanemiaandirondeﬁciency
among children infected with each species. It was found that
among children with N. americanus, anemia was prevalentin
60.5%and irondeﬁciencyanemia in33.1%.Among children
infected with A. duodenale, prevalence was 80.55% and
58.9%,respectively,suggestingthatA.duodenaleisassociated
with a greater burden of iron deﬁciency [40].Anemia 3
Hookworm is unique among helminths in that infection
intensities tend to peak in adulthood [43]. Rather than
peaking in childhood and adolescence and then declining as
is the case of many other parasitic infections, the intensity of
hookworm infection follows a steady rise during childhood
and does not reach a peak or plateau until adulthood [42].
A study conducted in Hainan Province, China, which exam-
ined risk factors associated with N. americanus in people 50
years of age and older, found that age still accounted for 27%
of the variation in the intensity of hookworm infection [44].
This is likely due to the fact that neither age- nor exposure-
related immunity develops in the majority of hookworm-
infected people [45]. This further supports the concern that
hookworm infection may continue to aﬀect work capacity
among the most productive members of society.
The association between hookworm infection intensity
and increasing age has serious implications for women of
reproductive age who are already at risk for anemia due
to low iron stores related to poor dietary intake, menstrual
blood loss, and pregnancy. Hookworm is likely a major
contributor to the adverse birth outcomes associated with
iron deﬁciency anemia, most notably low birth weight [46].
In a randomized, double blind placebo controlled trial
among pregnant women in Sri Lanka, the proportions of
stillbirths and perinatal deaths were signiﬁcantly lower in
thegrouptreated with mebendazole compared tothe control
group (1.9 versus 3.3%, 0.55 (95% CI 0.4–0.77)), as was the
proportion of low-birthweight babies (1.1 versus 2.3%, 0.47
(95% CI 0.32–0.71)). Of note, the authors found a slight
increase in the odds for major congenital defects among
the women who received mebendazole, “contrary to medical
advice,” during the ﬁrst trimester only (odds ratio 1.66 (0.1–
3.56), P = .23). In a separate study conducted in Uganda,
where the prevalence of maternal anemia was 40% at enroll-
m e n t ,i n v e s t i g a t o r sf o u n dn oo v e r a l le ﬀect of albendazole on
maternal anemia or birthweight, but a suggestion of beneﬁt
foranemiaamongwomenwith moderatetoheavyintensities
of hookworm infection at baseline (OR 0.45; 95% CI, 0.21–
0.98; P = .15 for interaction).
There has been signiﬁcant debate regarding the role
of soil-transmitted helminths (STH), which include hook-
worm, ascaris, and trichuris, in cognitive impairment.
Though other mechanisms have been discussed [47], iron
deﬁciency is consistently proposed as a primary mechanism
leading to cognitive impairment. Many factors have con-
tributed to conﬂicting results. Of note, early cross-sectional
studies that demonstrated relationships between soil-trans-
mitted helminths (STH) and cognitive function have been
criticized for lack of control for important confounders such
as SES [47]. While some cross-sectional studies that have
adjusted for potential confounders have found a relationship
between cognitive performance and STH infection [48],
other studies have not. Further, randomized controlled
trials examining the eﬀects of treatment for STH have had
diﬀering results [28, 49]. A recent meta-analysis addressing
the topic of treatment for STH and cognitive outcomes
concluded that a relationship between antihelmintic treat-
ment and improved cognitive performance could not be
determined [50]. This papaer noted that the quality of
even the randomized controlled trials was generally poor.
This meta-analysis was highly controversial, with many
ensuing published and unpublished diﬀerences of opinion
[51–54]. One major critique was that baseline infection
status of the children was not determined in the majority
of trials included, such that both infected and uninfected
children were randomized and treated. This “mass treat-
ment” approach leads to an underestimation of the eﬀect
of treatment among those who are infected with STHs. In
fact, onecritiquenoted that among the studies that were able
to stratify analyses by baseline infection status, a treatment
eﬀect was seen [49]. In addition, studies were conducted in
parts of the world with varying intensities of each STH and
with drugsthat havevarying eﬀecto nea c hST H.I na ddi ti o n ,
short follow-up periods in the context of randomized
controlledtrialsmayhavealsoobscuredtheabilitytocapture
improvements, as children likely need to recover iron stores
before signiﬁcant gains can be appreciated. Finally, children
with long-standing helminth infections may develop deﬁcits
in the actual ability to learn and process new information,
which may take long periods of time to develop or reacquire.
Conclusions from this meta-analysis are thus limited to the
impact of a mass treatment approach, which may not lead
to signiﬁcant improvements in cognitive performance in a
target population with varying intensities of infection. It
is likely, however, that among children who are infected,
particarly at higher intensities of infection, treatment does
lead to improvement in speciﬁc areas of cognitive function
[49]. Despite these controversies, expected improvements in
cognitive and school performance have been among the key
reasons cited in recent initiatives for widespread, regular
antihelmintic treatment of school children in endemic areas
[42, 55].
4.Schistosomiasis:Iron DeﬁciencyAnemia
and Anemia ofInﬂammation
A number of cross-sectional studies have examined the rela-
tionship between the three most prevalent human schisto-
somes andanemia [8,56–62].However,duetothenumerous
nutritional deﬁciencies and infectious diseases that co-
exist with schistosome infections, which are also related to
increased risk for anemia, careful control for confounding
variables or use of an experimental design is necessary to
quantify this association. Recent cross-sectional studies have
better adjusted for potential confounders, allowing for an
improved estimation of the true relationship between schis-
tosomiasis and anemia [59–61]. These recent studies have
observedan inverserelationship between S.japonicuminten-
sity of infection [60, 61] and hemoglobin, and S. haemato-
biuminfection andriskofanemiaamongyoungchildrenand
adolescents [59].
Many randomized controlled trials have found that ther-
apy with praziquantel and albendazole [63–65]o rm e t r i -
fonate [66, 67], which is eﬃcacious against schistosome
and hookworm infections, leads to improvements in hemo-
globin. The use of combination therapy makes inferences
regarding the schistosomiasis-attributable beneﬁt of treat-
ment for anemia diﬃcult, though most authors suggest that4 Anemia
aportion ofobservedimprovementinhemoglobinwaslikely
due to reduced schistosome burden.
Only two randomized controlled trials have been con-
ducted utilizing monotherapy with a drug eﬃcacious pre-
dominantly against schistosomes [68, 69]. One study con-
ducted in an S. japonicum endemic village in Leyte, the Phil-
ippines demonstrated signiﬁcant diﬀerences in hemoglobin
sixmonthsaftertherapybetweenchildrenintheintervention
andcontrolarms.Themagnitudeofeﬀectwasapproximately
1.1g/dL. Of note, males experienced a greater increase in
hemoglobin with treatment than did females. The experi-
mental design of this study and the “isolation” of schistoso-
miasis support a role for S. japonicum in the etiology of ane-
mia in regions of the developing world where it is endemic.
Another randomized controlled trial examined praziquantel
treatment alone for S. haematobium,a n df o u n dn oe ﬀect
of treatment on hemoglobin [68]. This is unlikely to be
due to lack of statistical power (N = 104 in placebo and
105 in praziquantel), low prevalence of anemia (70%), or
inadequate followup (eight months). However, it is possible
that this null ﬁnding was due to the exclusion of children
with high intensity infections.
4.1. Anemia of Inﬂammation. Anemia of inﬂammation must
be mentioned in the context of iron status in LDCs, as
this process leads to both decreased iron absorption and
sequestration of iron into storage forms, rendering it less
availabletohost tissues. Further, theetiologyofanemia (iron
deﬁciency anemia or anemia of inﬂammation, or both) is
diﬃcult to determine in the developing world context where
assays to determine biomarkers of iron status are not avail-
able. Anemia of inﬂammation is characterized by decreased
red blood cell production through a series of mechanisms,
mediated in part by proinﬂammatory cytokines, particularly
TNF-alpha and IL-6. These mechanisms includesuppression
of the normal response of bone marrow to erythropoi-
etin,decreasedsynthesis oferythropoietin,dyserythropoiesis
(disturbances of bone marrow cellular division), and alter-
ations in iron metabolism such that iron is sequestered into
storage forms, such as ferritin, making it less bio-available
[70].
Recently, major advances have been made in our under-
standing of anemia of inﬂammation [71]. In response to
inﬂammation, in particular IL-6, hepcidin is synthesized
[72].This proteinhas pleiotropiceﬀectsonironmetabolism.
Hepcidin causes sequestration of iron from bio-available
formstostorageforms,aswellasdecreasedintestinalabsorp-
tion of iron [73, 74]. Both processes are due to the binding
of hepcidin to ferroportin, the only iron egress protein
in humans. Hepcidin-ferroportin binding causes the inter-
nalization anddegradationofferroportin [75],thustrapping
iron inside cells. This results in the inability to absorb iron
from the gut and to mobilize iron from reticuloendothelial
macrophages [73, 76, 77]. In the proximal small intestine,
iron is trapped in intestinal epithelial cells and lost during
normalcellturnover[74,78].Decreasedabsorption andiron
sequestration leads to decreased iron bio-availability to meet
needs such as erythropoeisis. This is of great public health
importance given that anemia of inﬂammation contributes
to, or is the primary cause of, anemia in the context of many
commoninfectious diseases in LDCsincludingmalaria, HIV,
schistosomiasis, tuberculosis, and others [7, 14, 62, 79, 80].
4.2. HIV. While HIV is not a signiﬁcant cause of iron deﬁ-
ciency anemia, its role as a major cause of anemia in LDCs
warrants special mention due to the “functional” iron deﬁ-
ciency caused by HIV-related anemia of inﬂammation. Ane-
mia is highly prevalent among people with HIV-infection,
and has been identiﬁed as a marker for disease progression
and associated with decreased survival [3, 81–83]. There is
signiﬁcant evidence to support anemia of inﬂammation as
the primary cause of anemia in the context of HIV infection
[3]. A study conducted among infants in Uganda found the
prevalence of IDA (Hb < 11.0g/dL and ferritin < 12g/L) to
be approximately equal among HIV-infected and uninfected
infants, with prevalence of any anemia signiﬁcantly higher
in the HIV-infected group than the uninfected group (90.9%
and 76.9%, resp.). The authors attribute the excess anemia
among HIV-infected infants to anemia of inﬂammation [3,
84]. Another study conducted among antiretroviral-na¨ ıve
HIV-infected children in South Africa found that prevalence
of anemia increased with HIV disease stage from 42% for
children with no evidence of immunosuppression to 85%
forchildrenwith severeimmunosuppression. Irondeﬁciency
anemia was present in only 17% of the children, further
supporting the primary role of anemia of inﬂammation in
the pathogenesis anemia in the context of HIV infection
[3, 85].
5.Trichuris
The prevalence of infection with T. trichiura in the devel-
oping world is high, approaching 95% in areas of endem-
nicity and aﬀecting an estimated 1049 million people
[86]. Although low-intensity infections with T. trichiura
appear to be asymptomatic, high-intensity infections and
Trichuris Dysentery Syndrome (TDS) are associated with
growth stunting and anemia [87, 88]. Potential mechanisms
of trichuris-related anemia include worm consumption of
blood in the context of heavy infections, colonic lesions
with associated bleeding, or chronic reduction in food and
micronutrient intake due to the anorexia inducing eﬀects
of TNF-alpha released in response to infection [86, 89]. Of
note, one study assessing occult blood loss with T. trichiura
found that trichuriasis does not lead to signiﬁcant occult
gastrointestinal bleeding in the absence of TDS [90].
6.BacterialDysentery Syndromes
Occultblood lossdueto ShigellosisorEnteroinvasive Escher-
ichia coli dysentery may contributetoiron deﬁciencyanemia
among infants and children in areas of the developing world
where these pathogens cause frequent childhood illness.
Absolute blood loss due to dysentery or its contribution to
IDA have not been well quantiﬁed.Anemia 5
7.Helicobacter pylori
The greatest prevalence of H. pylori is in LDCs, where the
majority of infections are acquired during early childhood
[91, 92]. H. pylori neutralizes and decreases secretion of
gastric acid resulting in hypochlorhydria, and causes chronic
inﬂammation ofthegastrointestinal tract. Studiesconducted
among both adults and children have implicated H. pylori as
a cause of iron deﬁciency anemia [92–97]. It is hypothesized
that H. pylori-associated iron deﬁciency anemia is caused
by both compromised absorption of bioavailable iron in
the context of hypochlorhydria, and the competing iron
demands of H. pylori and the host [92, 98, 99].
8.Malaria
Malaria is a major contributor to anemia in the developing
world. Though the primary cause ofanemia in the contextof
malaria is hemolytic, studies have demonstrated that anemia
of inﬂammation plays an important role as well by inducing
c h a n g e si ni r o na b s o r p t i o na n dd i s t r i b u t i o n[ 14, 100]. Both
clinical and asymptomatic malaria have been associated
with anemia of inﬂammation. In a study in Indonesia,
de Mast et al. found that asymptomatic children with P.
falciparum or P. vivax parasitemia had signiﬁcantly lower
hemoglobin concentrations than aparasitemic controls (12.6
and 12.2g/dL versus 14.4g/dL; P<. 0 1 ) ,a sw e l la ss i g n i ﬁ -
cantlyhigherserumhepcidinconcentrations(5.2and5.6nM
versus 3.1nM; P<. 05) [100]. These results support the
concept that prolonged sequestration of iron into storage
forms due to inﬂammation caused by malaria parasitemia is
likely a major cause of anemia in the developing world.
Exceptionally high rates of maternal morbidity and mor-
tality are a major concern in the developing world, particu-
larly in sub-Saharan Africa [101]. Much of this excess mor-
bidity and mortality is attributable to malaria [102, 103].
Risk of malarial infection is especially high in HIV-infected
individuals [104]. Studies have shown that HIV infection
contributes to the burden of malarial anemia by increasing
risk for parasitemia, severe anemia, and treatment failure
[3]. Women are more susceptible to P. falciparum malaria
during pregnancy, and the risk of disease and death is high
for both the mother and her fetus. In areas of stable
malaria transmission, an estimated one in four women has
evidence of malarial infection at the time of delivery [105].
This underestimates the burden throughout gestation as it
is ascertained only at delivery and does not take into
account eﬀects of infections preceding delivery [103]. In
stable transmission areas, severe maternal anemia and low
birth weight are frequent sequelae and account for an enor-
mous loss of life [106, 107]. To address this, WHO re-
commends provision of intermittent prophylactic treatment
in pregnancy (IPTp) to reduce the risk of pregnancy
malaria and related in malaria-endemic regions. IPTp entails
provision of sulfadoxine-pyrimethamine (SP) during the
secondandthirdtrimester [107].EarlystudiesfoundthatSP-
IPTp signiﬁcantly reduced the frequency of both placental
and peripheral parasitemia [108–110], increased maternal
hemoglobin levels, and reduced the prevalence of moderate
to severe anemia [108, 111]. Approximatelyone in four cases
of severe maternal anemia may be prevented with adequate
prevention of malaria during pregnancy [112]. There is
growing concern, however, with respect to malaria resistance
to SP and the eﬃcacy of this regimen [113]. New studies
are underway to evaluate the safety and eﬃcacy of newer
antimalarial drugs in pregnancy.
Treatment for malaria and anemia in LDCs is further
complicated by concerns that provision of iron in malaria
endemic regions may increase the risk for malaria-related
morbidity and mortality [114–116]. Studies in Tanzania
found that pregnant women who were iron-replete versus
iron-deﬁcientat deliverywere three times morelikelytohave
placental parasitemia [114, 117]. In addition, among iron-
replete mothers, placental malaria led to an increased risk of
anemia among newborns [117]. The deleterious interaction
betweenironandmalaria hasalsobeendemonstratedamong
children. Iron plus folate supplementation given during a
recent randomized, placebo-controlled trial in a high P.
falciparum transmission area of Zanzibar resulted in a 15%
increase inallcausemortality[116].Enhancedmalarial mor-
bidity was concentrated in children who were iron-replete
at baseline. Children receiving iron and folate suﬀered 16%
(P = .02) greater risk of clinical malaria and a 70% greater
risk (P = .02) of cerebral malaria. In a separate study in
Kenya, clinical malaria was signiﬁcantly less frequent among
iron-deﬁcient children [118]. In Papua New Guinea, iron
supplementationincreasedtheprevalenceofparasitemiaand
splenomegaly among infants [119]. Iron supplementation
didnot,however,increase therisk ofmalaria amongchildren
under intensive health surveillance in Kenya [120]. Taken
together,theseﬁndingssuggestthatroutinesupplementation
with iron may place populations in malaria endemic settings
atincreasedriskformalaria-speciﬁc morbidityandmortality
[116]. Eﬀects of baseline iron status, acquired immunity,
or intensity of health surveillance could explain some of
the variability in results. Further studies are warranted and
underway to more clearly evaluate the balance of risks and
beneﬁts and potential eﬀect modiﬁers of this risk for speciﬁc
populations.
9.Iron SupplementationinPregnancy
Despite WHO recommendations to provide prenatal vita-
mins with iron [121], studies do not support an association
between iron interventions and birth outcomes [122, 123].
A recent Cochrane review of this topic reaﬃrmed this con-
clusion [124], and a separate earlier review concluded that
“the currently available evidence from studies with designs
appropriate to establish a causal relationship is insuﬃcient
to support or reject the practice (prenatal iron supplemen-
tation) for the speciﬁc purposeso fr a i s i n gb i r t hw e i g h to r
lowering the rate of preterm birth” [122]. This is further
supported by animal data including a primate study of
iron supplementation during pregnancy [125]. In that study
using Rhesus monkeys,neonatal neurobehavioraltest scores,
number of stillbirths, birth weight, and maternal weight
gain were not signiﬁcantly diﬀerent between dams fed a diet
containing iron (100µg Fe/g) and those monkeys deprived6 Anemia
of iron (<10µg Fe/g). Further, maternal monkeys receiving
the iron-replete diet did diﬀer signiﬁcantly in hematocrit,
MCV, transferrin saturation, serum ferritin, and serum iron
compared to those receiving an iron-deplete diet. However,
newborn monkeys did have higher hemoglobin values with
maternal supplementation.
Ongoing discrepancies across studies with respect to
beneﬁts of iron supplementation during pregnancy are likely
due to the underrecognized role of anemia of inﬂammation
in the developingworld. This is highlighted by a recent study
thatexaminedawiderangeofnutritionalandnonnutritional
causes of anemia in pregnancy in Malawi, including bone
marrowaspiration[6].InvestigatorsfoundthatCRPconcen-
trations were elevated in 54% of anemic pregnant women
with no nutritional deﬁciencies and in 73.5% of the anemic
women who were iron-replete by bone marrow assessment.
Thisstudydemonstratestheimportantroleplayedbyanemia
of inﬂammation in the pathogenesis of anemia in pregnancy.
In the context of anemia of inﬂammation, the absorption of
prenatal iron supplements will be limited and absorbed iron
will be shunted from bio-available forms to storage forms,
limiting maternal use and potentially inhibiting delivery of
iron to the fetus. The possible exacerbation of malaria-
related morbidity in pregnancy associated with provision
of prenatal iron may also explain disparate ﬁndings, if iron
provision in this context is increasing malarial anemia [114,
117].
Other beneﬁts of prenatal iron supplementation have
been identiﬁed, however. In particular, many studies have
demonstrated improvements in maternal hemoglobin with
prenatal iron supplementation [123]. This may be of greater
signiﬁcance in the developing world where there is a higher
prevalence of moderate to severe iron deﬁciency anemia
with consequent greater risk of perinatal mortality related
to postpartum hemorrhage. Prenatal iron supplementation
may also have beneﬁcial eﬀects for the newborn. Preziozi et
al. found that newborn iron status is dependent on maternal
iron status during pregnancy and that children born to iron-
treated mothers have higher serum ferritin, greater body
length, and increased Apgar scores in comparison to those
treated withplacebo[126].OtherstudiesconductedinLDCs
have shown that concentrations of hemoglobin, iron, and
ferritin are signiﬁcantly lower in the cord blood newborns
of anemic mothers, with linear relationships demonstrated
with maternal hemoglobin and ferritin levels [2].
9.1. Diagnosis and Treatment. Despite the enormous global
burden of disease due to anemia and the multiple causes
of anemia in LDCs, diagnostic tests to distinguish primary
etiologies are limited, particulary in these cost-constrained
settings. Given iron deﬁciency anemia (due to dietary insuf-
ﬁciencyand infectiousdiseases) and anemiaofinﬂammation
are the two leading causes of anemia in LDCs, and interven-
tions to address these diﬀer, diagnostic tools to diﬀerentiate
the two are of paramount importance.
Until recently, there has been a lack of valid biomarkers
to distinguish the causes of anemia. Hemoglobin and ferritin
have proven to be poor diagnostic tools [127], largely due
to the fact that ferritin is decreased in the context of iron
deﬁciency, but increased in the context of anemia of in-
ﬂammation as iron is sequestered in storage forms. The
emergence of hepcidin as a biomarker for anemia of inﬂam-
mation may help to ﬁll this diagnostic gap, and assist in
eﬀectively selecting individuals who will beneﬁt most from
iron therapy [100]. Treatment of anemia of inﬂammation
requires diagnosis and treatment of the underlying causes
of inﬂammation, highlighting the importance of treatment
programs for HIV, helminth infections and malaria (both
clinical and subclinical) in curbing anemia in the LDCs.
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